AI For Pharma Growth
AI For Pharma Growth is a podcast hosted by Dr. Andree Bates, an AI entrepreneur, aimed at helping pharma, biotech and healthcare companies understand how AI-based technologies can save time and grow their brands and business results. The show combines her deep sector experience with straightforward explanations of AI for biopharma executives, from biotech start-ups to large pharmaceutical firms. Episodes cover practical, proven approaches to building results with AI as well as interesting new tools and applications. Guests include experts who have developed powerful AI-powered tools behind time-saving and revenue-generating business outcomes.
Episodes
-
E244: What 10 years of building an AI Diagnostic start up teaches about real world AI vs lab AI 18.11.2026 31mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dejan Nenov of Lumanix about what a decade of building AI diagnostics has taught him about the difference between laboratory performance and real-world clinical utility.Dejan explains how Lumanix began with a simple observation: dogs can detect disease from urine. By combining gas chromatography with machine learning, the team set out to recreate that capability in a repeatable, scalable diagnostic platform.The conversation explores why real-world diagnostic AI needs far more than a high validation score. Lumanix tests across... -
E243: Rewiring Judgment: Why Pharma AI Fails as a Human Problem, Not a Technical One 11.11.2026 23mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr Eugene Chan of Behavieural about why many AI failures in pharma are not really technical failures at all. They are human problems involving trust, judgement, behaviour and adoption.Eugene explains that even when the technology works, people may ignore it, override it or over-trust it. Clinicians, scientists and executives bring their own biases, habits, incentives and sense of professional identity to every AI-assisted decision.The conversation explores why autonomy matters, how cognitive load changes behaviour, and why on... -
E242: The diagnostic room: HTA Expectations for AI-Generated Evidence: NICE, CDA-AMC and the EU JCA Principles 04.11.2026 37mIn this solo episode of AI For Pharma Growth, Dr Andree Bates explores what health technology assessment bodies now expect when AI is used to generate, analyse or support evidence.The episode looks at the emerging principles from NICE in England, CDA-AMC in Canada and the EU Joint Clinical Assessment framework. While none of these bodies has banned AI, Andree explains that organisations are increasingly expected to be able to justify where AI was used, how it was used, who was responsible for checking it and whether the process can be reconstructed.She breaks the expectations into four core ar... -
E241: Beyond the Survey: How Generative AI Captures the Patient Voice at Scale — and Why It's Pharma's Next Growth Lever 28.10.2026 35mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Mattia Marco Caruson, co-founder and CEO of mama health, about how generative AI is changing the way pharma understands the patient journey.Mattia explains why traditional methods such as surveys, focus groups and clinician interviews often capture only fragments of what patients actually experience. In rare and chronic diseases, the most important parts of the journey can happen between appointments, long before a patient reaches the right doctor or treatment.The conversation explores how generative AI can enable open-ended... -
E240: How secure and compliant data collaboration accelerates research and medical science 20.10.2026 27mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Kurt Rohloff, co-founder and CEO of Duality Technologies, about how privacy-enhancing technologies could unlock data collaboration without forcing organisations to give up control of sensitive information.Kurt explains how technologies such as fully homomorphic encryption and federated learning allow organisations to analyse encrypted or distributed data without exposing the underlying patient information. For pharma and medical research, that creates opportunities to reuse existing data, collaborate across organisations... -
E239: How to Speed Up Drug Development Without Compromising Compliance 13.10.2026 35mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Clara Bernardes, co-founder and CSO of Biorce, about how AI can accelerate clinical development without sacrificing compliance or scientific rigour.Biorce was born from a deeply personal experience. After Clara's father-in-law received a terminal melanoma diagnosis, access to a clinical trial through compassionate use extended his life from an expected three months to more than a year. That experience shaped Biorce's mission: reduce the time it takes promising treatments to reach patients.Clara explains why clinical trials ar... -
E238: The diagnostic room: The Fifteen Failures Only Human Judgement Catches 06.10.2026 39mIn this solo episode of AI For Pharma Growth, Dr Andree Bates explores one of the biggest blind spots in pharma AI: the failures that can survive a normal review process even when the output sounds polished, plausible and well grounded.Dr Andree explains why better models and better retrieval do not remove the need for human judgement. In fact, as AI systems improve, people often scrutinise them less. Fluent prose can create a false sense of reliability, while automation bias and anchoring make reviewers less likely to challenge the underlying frame.The episode introduces three broad families... -
E237: Beyond the Pill: How AI is Unlocking the Preventative Medicine Opportunity Pharma Can't Afford to Miss 29.09.2026 30mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with cancer biologist and health educator Rebecca Maff about how AI could help shift healthcare from treating disease to preventing it.Rebecca’s interest in prevention began after seeing women in her own family diagnosed with late-stage cancers and serious autoimmune conditions. Her subsequent work has included machine learning models designed to identify patients at higher risk of cancers and encourage overdue screening before disease progresses.The conversation explores what prevention really means in practice, from early biomar... -
E236: Why 90% of Trials Still Fail — and What AI Can (and Can't) Fix 22.09.2026 34mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Raviv Pryluk, co-founder and CEO of PhaseV, about why so many clinical trials still fail and where AI can genuinely improve the odds.Raviv argues that failure is often not because the drug itself is wrong. Trials can fail because of the wrong patient population, indication, dose, design, sites, monitoring or interpretation of the data. PhaseV uses causal machine learning, adaptive trial design and large-scale simulation to help sponsors make better decisions across those areas.The conversation explores why explainability and... -
E235: AI created a trust crisis and nobody is talking about it 15.09.2026 31mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dan Pratl, founder and CEO of Quadron Inc, about a trust problem emerging as AI moves deeper into pharma: how do organisations preserve confidence when more work is generated, shaped and accelerated by machines?Dan argues that verified output alone is not enough. Pharma already has human review, MLR, regulatory sign-off and quality controls, but trust also depends on understanding where data came from, which models were used, where human judgement entered the process and whether that chain can be audited.The conversation expl... -
E234: The contrarian case for physics over data: can deterministic, training-free models beat ML in lead optimization? 08.09.2026 43mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Jacek Marczyk, co-founder and CEO of BioDynLab, about a contrarian view of computational drug discovery: that the next leap may come not from more data and bigger models, but from physics.Dr. Marczyk brings a background in aerospace engineering, automotive, Silicon Graphics and complexity science. His work led to quantitative complexity theory, which he now applies to molecules through BioDynLab’s deterministic, training-free approach.The conversation explores why high precision and high complexity cannot coexist, and why... -
E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named 01.09.2026 43mIn this solo episode of AI For Pharma Growth, Dr Andree Bates explores the AI capability problem pharma has not properly named: training that works in the room, but fails to hold inside the organisation.Dr Andree explains why one-off workshops, generic AI fluency programmes and broad learning platforms are not enough. They may teach people what AI is, what it can do and where it can fail, but they rarely teach the exact workflows, judgement calls and regulatory context people need for their own roles.The episode looks at why AI capability fades over time. Some people leave training and build v... -
E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner 25.08.2026 28mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Tom Coates, CEO of Presentient, about why interim analysis in clinical trials is ready for a major upgrade.Interim analyses allow sponsors to look at trial data mid-flight and assess whether a study is likely to succeed or fail, using pre-specified rules. But Tom explains that many phase two and three commercial trials still do not include a pre-planned interim analysis, meaning sponsors often wait far longer than necessary to detect futility or act on early signs of success.The conversation explores how Presentient is workin... -
E231: The Diagnostic Room: You didn't have an AI problem. You had a capability problem. 18.08.2026 36mIn this solo episode of AI For Pharma Growth, Dr Andree Bates explores why many pharma teams do not have an AI problem at all. They have a capability problem.Dr Andree starts with a simple question: when was your team last properly trained on AI for their specific role? Not when they were given access to tools, licences or a generic use policy, but when they were trained to use AI effectively, safely and compliantly in their actual workflow.The episode challenges the usual explanations for disappointing AI results: the model was not good enough, the vendor was wrong, the data was not ready, or... -
E230: The Last Untouched Dataset 11.08.2026 23mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Nijat Ahmadov, CEO of Nucs AI, about molecular imaging as one of pharma’s most underused data assets.Nijat explains why PET, CT and other molecular imaging data remain largely “untouched”: clinically valuable and created at scale, but still too often trapped in qualitative reads rather than structured, standardised data that can support decision making. As radioligand therapies expand in oncology, that gap becomes harder to ignore.The conversation explores how AI can help turn molecular imaging into computable, decision-grade... -
E229: From Reactive to Proactive: What a QP's Job Should Actually Look Like in 2026 04.08.2026 33mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Jitesh Halai, founder and CEO of OneSC, about what the Qualified Person role should look like in a more proactive, digitally connected pharmaceutical supply chain.Jitesh explains how many QPs are still forced into reactive work: chasing documents, checking versions, searching inboxes, reconciling batch data across disconnected systems and trying to work out what is holding up release. In virtual pharma environments, where much of the supply chain is outsourced, that burden becomes even heavier.The conversation explores how pl... -
E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer 28.07.2026 40mIn this solo episode of AI For Pharma Growth, Dr Andree Bates explains why “we’re doing AI” is not a credible board answer, and why activity, pilots and steering committees are not the same as strategy.Dr Andree breaks down two common answers leadership teams give when asked about AI strategy. The episode explores why crowdsourced use cases often become “use case copying” rather than genuine internal innovation. A pain point may be real, and a pilot may work, but that does not mean it is one of the highest-value AI opportunities for the organisation. Without financial modelling, business-unit... -
E227: From Bench to Boardroom: How One Geneticist is Quietly Reshaping the Future of Healthcare 21.07.2026 33mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Bret Bostwick from Breyer Capital about the rare path from genetics, clinical medicine and drug development into venture capital, and what that perspective reveals about the future of healthcare innovation.Bret shares how the release of the Human Genome Project first pulled him into genetics, and how clinical work with patients made the science deeply practical. As a medical geneticist, he saw families finally receive a diagnosis, but often without a treatment option. That experience led him towards programmable therapeutics,... -
E226: The AI Deal Scout: How Machine Intelligence Is Reshaping Biopharma Business Development 14.07.2026 28mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Smbat Rafayelyan, founder and CEO of Bioneex, about how AI is reshaping biopharma business development, deal scouting and asset evaluation.Business development has traditionally relied heavily on relationships, conferences, databases, analyst reports and manual search. But as therapeutic pipelines, publications, patent filings and global biotech activity expand, that old model is becoming harder to sustain. Smbat explains why teams that only rely on their network risk missing valuable assets before they even know they were av... -
E225: The 80% Nobody Talks About: Building AI Governance That Survives a Pharma Audit 07.07.2026 31mIn this episode of AI For Pharma Growth, Dr Andree Bates speaks with Nuno Valério, Head of Innovation, R&D Quality at Merck Healthcare, about the part of AI governance most organisations rarely talk about: the operational 80% that decides whether AI survives a pharma audit.Nuno explains why governance cannot stop at policies, committees, risk frameworks and model registers. Those visible elements matter, but they are only the start. In a GxP environment, auditors will want to reconstruct how a decision was made, which data was used, which model version was involved, what validation evidence ex...
Popular in
The podcast also appears in the podcast charts of these countries.